Cargando…

Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea

OBJECTIVE: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Su Jin, Ahn, Soo Min, Oh, Ji Seon, Hong, Seokchan, Lee, Chang-Keun, Yoo, Bin, Kim, Yong-Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Rheumatology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324915/
https://www.ncbi.nlm.nih.gov/pubmed/37476702
http://dx.doi.org/10.4078/jrd.2022.29.1.22
_version_ 1785069202315411456
author Choi, Su Jin
Ahn, Soo Min
Oh, Ji Seon
Hong, Seokchan
Lee, Chang-Keun
Yoo, Bin
Kim, Yong-Gil
author_facet Choi, Su Jin
Ahn, Soo Min
Oh, Ji Seon
Hong, Seokchan
Lee, Chang-Keun
Yoo, Bin
Kim, Yong-Gil
author_sort Choi, Su Jin
collection PubMed
description OBJECTIVE: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role of renal function as a predictor of renal response METHODS: From 2016 to 2019, we retrospectively reviewed 22 patients with refractory/relapsing LN receiving rituximab Renal responses (complete and partial) at 6 and 12 months were compared between normal (glomerular filtration rate [GFR]≥90 mL/min/173 m(2), n=11) and decreased (GFR<90 mL/min/173 m(2), n=11) GFR groups Multivariate Cox regression analysis was used to assess predictors of renal response RESULTS: At baseline, the decreased GFR group had a higher urine proteinuria to creatinine ratio (p=0008) and proportion of refractory LN (p=0010) and previous cyclophosphamide therapy (p=0035) than the normal GFR group The overall renal response rate was 455% (10 patients) at 6 months and 545% (12 patients) at 12 months Renal response rates were higher in the normal GFR group (818% and 909% at 6 and 12 months, respectively) than in the decreased GFR group (91% and 182% at 6 and 12 months, respectively; p<0001) Normal GFR and anti-La were associated with renal response to rituximab, with hazard ratios of 9256 (p=0008) and 5478 (p=0041), respectively CONCLUSION: Rituximab is an effective therapy for refractory/relapsing LN, particularly in patients with preserved renal function
format Online
Article
Text
id pubmed-10324915
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean College of Rheumatology
record_format MEDLINE/PubMed
spelling pubmed-103249152023-07-20 Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea Choi, Su Jin Ahn, Soo Min Oh, Ji Seon Hong, Seokchan Lee, Chang-Keun Yoo, Bin Kim, Yong-Gil J Rheum Dis Original Article OBJECTIVE: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role of renal function as a predictor of renal response METHODS: From 2016 to 2019, we retrospectively reviewed 22 patients with refractory/relapsing LN receiving rituximab Renal responses (complete and partial) at 6 and 12 months were compared between normal (glomerular filtration rate [GFR]≥90 mL/min/173 m(2), n=11) and decreased (GFR<90 mL/min/173 m(2), n=11) GFR groups Multivariate Cox regression analysis was used to assess predictors of renal response RESULTS: At baseline, the decreased GFR group had a higher urine proteinuria to creatinine ratio (p=0008) and proportion of refractory LN (p=0010) and previous cyclophosphamide therapy (p=0035) than the normal GFR group The overall renal response rate was 455% (10 patients) at 6 months and 545% (12 patients) at 12 months Renal response rates were higher in the normal GFR group (818% and 909% at 6 and 12 months, respectively) than in the decreased GFR group (91% and 182% at 6 and 12 months, respectively; p<0001) Normal GFR and anti-La were associated with renal response to rituximab, with hazard ratios of 9256 (p=0008) and 5478 (p=0041), respectively CONCLUSION: Rituximab is an effective therapy for refractory/relapsing LN, particularly in patients with preserved renal function Korean College of Rheumatology 2022-01-01 2022-01-01 /pmc/articles/PMC10324915/ /pubmed/37476702 http://dx.doi.org/10.4078/jrd.2022.29.1.22 Text en Copyright © 2022 by The Korean College of Rheumatology. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Choi, Su Jin
Ahn, Soo Min
Oh, Ji Seon
Hong, Seokchan
Lee, Chang-Keun
Yoo, Bin
Kim, Yong-Gil
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title_full Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title_fullStr Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title_full_unstemmed Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title_short Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
title_sort initial preserved renal function as a predictor of favorable renal response to rituximab in refractory or relapsing lupus nephritis: a single-center cohort study in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324915/
https://www.ncbi.nlm.nih.gov/pubmed/37476702
http://dx.doi.org/10.4078/jrd.2022.29.1.22
work_keys_str_mv AT choisujin initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT ahnsoomin initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT ohjiseon initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT hongseokchan initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT leechangkeun initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT yoobin initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea
AT kimyonggil initialpreservedrenalfunctionasapredictoroffavorablerenalresponsetorituximabinrefractoryorrelapsinglupusnephritisasinglecentercohortstudyinkorea